Deepull

Description

Deepull develops the UllCORE BSI test and supporting instrument that perform direct-from-blood multiplex molecular detection of pathogens and antibiotic resistance markers, producing about 50 reportable results in roughly one hour for sepsis diagnosis.

Deepull is located in the Barcelona ecosystem.

Related

• GradientechGradientech develops the QuickMIC system for ultra-rapid phenotypic antibiotic susceptibility testing, producing precise MIC values for…
• ADmit THERAPEUTICSADmit THERAPEUTICS develops and commercializes MAP-AD®, an in vitro diagnostic test using mitochondrial DNA epigenetic biomarkers, NGS and…
• Nimble DiagnosticsNimble Diagnostics develops a non-invasive, portable monitoring device that detects stent complications, measuring stent malfunction with…
• NucleraNuclera builds and supplies eProtein Discovery systems, cartridges, reagents and services for multiplex cell-free protein screening used by…
• numares HEALTHnumares HEALTH develops biomarker tests that use nuclear magnetic resonance spectroscopy and machine learning to quantify serum metabolites…
• ALLOXALLOX uses high-throughput experiments with genetics and AI to learn biophysical parameters of protein function, supporting systematic…
• Cyted HealthCyted Health combines minimally invasive cell collection with molecular analysis to build diagnostic tests (EndoSign®) for earlier…
• FluIDectFluIDect develops industrial biosensors that use light-emitting microbeads as target-specific messengers for inline, real-time detection of…
• NETRIS PharmaNETRIS Pharma develops therapeutics that target Netrin-1 to overcome resistance to oncology treatments, producing monoclonal antibodies…